Enhertu showed better outcomes in HR-positive, HER2-negative breast cancer, while Trodelvy was more effective in HR-negative, HER2-null tumors when used first. Real-world data from over 4,000 patients ...
Hosted on MSN
For your patients: What to know about the newest treatments for HR+/HER2- breast cancer
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This ...
Imlunestrant is approved for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, showing improved progression-free survival with abemaciclib. The oral administration of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results